• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Stocks That Hit 52-Week Lows On Monday

    1/9/23 11:20:01 AM ET
    $ARVN
    $CERS
    $CIO
    $CUTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    EDP Services
    Technology
    Get the next $ARVN alert in real time by email

    Companies That Fell Through 52-Week Lows Monday

    During Monday's morning trading, 14 companies set new 52-week lows.

    Things to Consider About Today's 52-Week Lows:

    • L3Harris Technologies (NYSE:LHX) was the biggest company on a market cap basis to set a new 52-week low.
    • The smallest company by market cap to hit a new 52-week low was Nabriva Therapeutics (NASDAQ:NBRV).
    • Cutera (NASDAQ:CUTR) shares traded down 23.86% to reach its 52-week low, making it the biggest loser.
    • Nabriva Therapeutics (NASDAQ:NBRV)'s stock made the biggest reversal, trading up 0.77% shortly after dropping to a new 52-week low.

    Here is a list of stocks that set new 52-week lows on Monday:

    • L3Harris Technologies (NYSE:LHX) stock hit a new 52-week low of $200.33. The stock was down 1.31% on the session.
    • Arvinas (NASDAQ:ARVN) stock dropped to a yearly low on Monday of $27.00. Shares traded down 12.8%.
    • Cutera (NASDAQ:CUTR) shares hit a yearly low of $29.49. The stock was down 23.86% on the session.
    • Cerus (NASDAQ:CERS) shares set a new 52-week low of $3.06. The stock traded down 17.99%.
    • PMV Pharma (NASDAQ:PMVP) shares hit a yearly low of $8.08. The stock was down 3.23% on the session.
    • City Office REIT (NYSE:CIO) stock set a new 52-week low of $8.03 on Monday, moving down 1.72%.
    • PIMCO California (NYSE:PCQ) shares reached a new 52-week low of $12.20 on Monday morning, moving down 1.48%.
    • DLH Hldgs (NASDAQ:DLHC) stock hit a new 52-week low of $10.80. The stock was down 9.24% on the session.
    • Peak Bio (NASDAQ:PKBO) shares set a new yearly low of $2.84 this morning. The stock was down 11.93% on the session.

    Be sure to stay with Benzinga for further updates and market-moving news. And if you want to be among the first to know about the 52-week highs and lows for the day, check out Benzinga Pro. Users receive a daily alert listing stocks trading near 52-week highs and lows each morning. Click here to learn more.

    Get the next $ARVN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARVN
    $CERS
    $CIO
    $CUTR

    CompanyDatePrice TargetRatingAnalyst
    Arvinas Inc.
    $ARVN
    9/17/2025$16.00Overweight
    Barclays
    Arvinas Inc.
    $ARVN
    6/2/2025$9.00Outperform → Market Perform
    Leerink Partners
    Arvinas Inc.
    $ARVN
    5/5/2025$11.00Buy → Hold
    Truist
    Arvinas Inc.
    $ARVN
    5/2/2025$10.00Buy → Hold
    Jefferies
    Arvinas Inc.
    $ARVN
    5/2/2025Buy → Hold
    TD Cowen
    L3Harris Technologies Inc.
    $LHX
    4/11/2025$263.00Sell → Buy
    Goldman
    Arvinas Inc.
    $ARVN
    3/13/2025$70.00 → $15.00Buy → Neutral
    Goldman
    Arvinas Inc.
    $ARVN
    3/12/2025$57.00 → $12.00Outperform → Neutral
    Wedbush
    More analyst ratings

    $ARVN
    $CERS
    $CIO
    $CUTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays resumed coverage on Arvinas with a new price target

    Barclays resumed coverage of Arvinas with a rating of Overweight and set a new price target of $16.00

    9/17/25 7:57:56 AM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arvinas downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded Arvinas from Outperform to Market Perform and set a new price target of $9.00

    6/2/25 8:41:53 AM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arvinas downgraded by Truist with a new price target

    Truist downgraded Arvinas from Buy to Hold and set a new price target of $11.00

    5/5/25 8:28:44 AM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARVN
    $CERS
    $CIO
    $CUTR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Mink Brook Asset Management Llc bought $85,784 worth of shares (15,597 units at $5.50) (SEC Form 4)

    4 - DLH Holdings Corp. (0000785557) (Issuer)

    9/16/25 4:59:27 PM ET
    $DLHC
    Professional Services
    Consumer Discretionary

    Large owner Mink Brook Asset Management Llc bought $93,137 worth of shares (16,934 units at $5.50) (SEC Form 4)

    4 - DLH Holdings Corp. (0000785557) (Issuer)

    9/12/25 4:31:46 PM ET
    $DLHC
    Professional Services
    Consumer Discretionary

    Large owner Mink Brook Asset Management Llc bought $1,084 worth of shares (197 units at $5.50) (SEC Form 4)

    4 - DLH Holdings Corp. (0000785557) (Issuer)

    9/3/25 5:02:19 PM ET
    $DLHC
    Professional Services
    Consumer Discretionary

    $ARVN
    $CERS
    $CIO
    $CUTR
    SEC Filings

    View All

    Arvinas Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - ARVINAS, INC. (0001655759) (Filer)

    9/17/25 4:32:51 PM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by PMV Pharmaceuticals Inc.

    144 - PMV Pharmaceuticals, Inc. (0001699382) (Subject)

    9/10/25 6:50:45 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMV Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Regulation FD Disclosure

    8-K - PMV Pharmaceuticals, Inc. (0001699382) (Filer)

    9/10/25 12:04:39 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARVN
    $CERS
    $CIO
    $CUTR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation

    Arvinas and Pfizer plan to jointly select third party for the out-licensing and commercialization of vepdegestrant Additional cost optimization measures expected to realize total annual savings of more than $100 million compared to FY 2024 Board authorizes stock repurchase program of up to $100 million Reaffirms cash runway guidance through the second half of 2028 NEW HAVEN, Conn., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN) today provided an update on its collaboration with Pfizer Inc. (NYSE:PFE) for the co-development of vepdegestrant, an investigational oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor protein degrader, and announced additional corpo

    9/17/25 4:30:26 PM ET
    $ARVN
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    City Office REIT Announces Preferred Stock Dividends for Third Quarter 2025

    VANCOUVER, Sept. 15, 2025 /PRNewswire/ -- City Office REIT, Inc. (NYSE:CIO) ("City Office," "CIO" or the "Company") announced today that its Board of Directors has authorized a quarterly dividend of $0.4140625 per share of the Company's 6.625% Series A Cumulative Redeemable Preferred Stock.  The dividends will be payable on October 24, 2025 to preferred stockholders of record as of the close of business on October 10, 2025. As previously disclosed, City Office's Board of Directors has resolved to suspend future quarterly common stock dividend payments through the close of the

    9/15/25 4:05:00 PM ET
    $CIO
    Real Estate Investment Trusts
    Real Estate

    L3Harris Receives Multi-Year Javelin Solid Rocket Motor Contract

    L3Harris Technologies (NYSE:LHX) has received a contract valued up to $292 million to continue its role producing propulsion for the Javelin weapon system. The award is the largest propulsion production contract received to date for the Javelin program, representing a production extension for five years. "Javelin provides a key capability for the United States, allies and partners," said Ken Bedingfield, President, Aerojet Rocketdyne, L3Harris. "Our ongoing investments in modernized solid rocket motor manufacturing will allow us to increase production capacity for Javelin by incorporating the latest advancements in automation into the motor casting and installation processes." L3Harris

    9/15/25 12:00:00 PM ET
    $LHX
    Industrial Machinery/Components
    Industrials

    $ARVN
    $CERS
    $CIO
    $CUTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Mink Brook Asset Management Llc bought $85,784 worth of shares (15,597 units at $5.50) (SEC Form 4)

    4 - DLH Holdings Corp. (0000785557) (Issuer)

    9/16/25 4:59:27 PM ET
    $DLHC
    Professional Services
    Consumer Discretionary

    Chair and CEO Kubasik Christopher E sold $23,231,700 worth of shares (83,000 units at $279.90) and converted options into 83,000 shares (SEC Form 4)

    4 - L3HARRIS TECHNOLOGIES, INC. /DE/ (0000202058) (Issuer)

    9/12/25 6:02:41 PM ET
    $LHX
    Industrial Machinery/Components
    Industrials

    Large owner Orbimed Advisors Llc sold $900,000 worth of shares (500,000 units at $1.80) (SEC Form 4)

    4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)

    9/12/25 5:09:08 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARVN
    $CERS
    $CIO
    $CUTR
    Leadership Updates

    Live Leadership Updates

    View All

    Arvinas Announces Retirement of Chief Executive Officer and Succession Plan

    – John Houston, Ph.D., Chairperson, CEO and President at Arvinas, Announces Plans to Retire as CEO Upon Appointment of Successor – – Dr. Houston to Remain Chairperson of Arvinas Board of Directors – – Arvinas Board of Directors to Lead Search for CEO Replacement – NEW HAVEN, Conn., July 09, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that John Houston, Ph.D., Chairperson, Chief Executive Officer (CEO) and President at Arvinas, has informed the Board of Directors of his plans to retire from his role as President and CEO following a search for, an

    7/9/25 7:00:00 AM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    L3Harris Appoints Trane Technologies Chair and CEO Dave Regnery to Board of Directors

    L3Harris Technologies (NYSE:LHX) today announced that David S. Regnery, Chair and Chief Executive Officer of Trane Technologies plc, has been appointed to its Board of Directors. "Dave is a strong business leader with proven success in business transformation, putting the customer first and creating a culture where innovation and accountability are important drivers of business decisions," said Christopher E. Kubasik, Chair and CEO, L3Harris. "His established track record of leading large organizations and shaping Trane Technologies' future strategy will be important to L3Harris as we continue our journey as the industry's Trusted Disruptor in support of our customers' most critical needs.

    10/15/24 6:45:00 PM ET
    $LHX
    Industrial Machinery/Components
    Industrials

    Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update

    – Completed enrollment in the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting; continued enrollment globally in multiple clinical trials of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting– – Completion of enrollment in VERITAC-2 expected in 4Q24 and topline data readout now expected 4Q24/1Q25 – – Received $150 million upon close of ARV-766 license agreement and sale of preclinical AR-V7 program to Novartis; potential for up to an additional $1.01 billion based on achievement of development, regulatory and commercial milestones and future royalties – – Strengthened executive team with the appointm

    7/30/24 7:00:00 AM ET
    $ARVN
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARVN
    $CERS
    $CIO
    $CUTR
    Financials

    Live finance-specific insights

    View All

    City Office REIT Announces Preferred Stock Dividends for Third Quarter 2025

    VANCOUVER, Sept. 15, 2025 /PRNewswire/ -- City Office REIT, Inc. (NYSE:CIO) ("City Office," "CIO" or the "Company") announced today that its Board of Directors has authorized a quarterly dividend of $0.4140625 per share of the Company's 6.625% Series A Cumulative Redeemable Preferred Stock.  The dividends will be payable on October 24, 2025 to preferred stockholders of record as of the close of business on October 10, 2025. As previously disclosed, City Office's Board of Directors has resolved to suspend future quarterly common stock dividend payments through the close of the

    9/15/25 4:05:00 PM ET
    $CIO
    Real Estate Investment Trusts
    Real Estate

    Drone as a Service Market Disrupting Both Government & Commercial Sectors While Experiencing Exponential Growth

    MarketNewsUpdates News Commentary NEW YORK, Aug. 7, 2025 /PRNewswire/ -- The Drone as a Service (DaaS) market, encompassing both government and commercial sectors, is experiencing rapid growth, driven by technological advancements, evolving regulatory frameworks, and increasing demand for efficient and cost-effective aerial solutions across various industries.  According to an article published by Verified Market Reports, "The market is characterized by its flexibility and scalability, allowing companies to utilize drone capabilities for specific tasks such as surveying, monitoring, and data collection. Industries such as agriculture, construction, logistics, and environmental management are

    8/7/25 9:30:00 AM ET
    $EH
    $JOBY
    $KTOS
    Aerospace
    Industrials
    Military/Government/Technical
    Industrial Machinery/Components

    Modiv Industrial Announces Second Quarter 2025 Results

    Modiv Industrial, Inc. ("Modiv Industrial," "Modiv" or the "Company") (NYSE:MDV), the only public REIT exclusively focused on acquiring industrial manufacturing real estate, today announced operating results for the second quarter ended June 30, 2025. Highlights: Second quarter 2025 revenue of $11.8 million and net loss attributable to common stockholders of $(2.8) million. Second quarter AFFO of $4.8 million, or $0.38 per diluted share, a 22% year-over year increase, beating consensus estimates. 5-year lease renewal with 2% annual escalations on our Northrop Grumman property located in Melbourne, Florida. The following is a statement from Aaron Halfacre, CEO of Modiv Industri

    8/7/25 6:00:00 AM ET
    $BLK
    $CIO
    $MDV
    Investment Bankers/Brokers/Service
    Finance
    Real Estate Investment Trusts
    Real Estate

    $ARVN
    $CERS
    $CIO
    $CUTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by PMV Pharmaceuticals Inc.

    SC 13G - PMV Pharmaceuticals, Inc. (0001699382) (Subject)

    12/12/24 12:29:41 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by City Office REIT Inc.

    SC 13G/A - City Office REIT, Inc. (0001593222) (Subject)

    11/14/24 4:05:11 PM ET
    $CIO
    Real Estate Investment Trusts
    Real Estate

    Amendment: SEC Form SC 13G/A filed by Arvinas Inc.

    SC 13G/A - ARVINAS, INC. (0001655759) (Subject)

    11/14/24 1:22:38 PM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care